PMH-C Psychopharmacology 5 — Questions and Answers
Question 1: A perinatal patient with ADHD asks about stimulant medication safety during breastfeeding. What is the most accurate statement?
- Amphetamines are completely safe and have AAP approval for breastfeeding
- Data are limited; amphetamines concentrate in breast milk and infant exposure warrants careful consideration (Correct answer)
- Stimulants have no transfer into breast milk
- Methylphenidate is FDA-approved specifically for lactating mothers
Correct answer: Data are limited; amphetamines concentrate in breast milk and infant exposure warrants careful consideration
Amphetamine-based stimulants concentrate in breast milk with milk-to-plasma ratios >1, so use during breastfeeding requires individualized risk-benefit discussion.
Question 2: Which physiological change in pregnancy most significantly affects the volume of distribution of psychotropic medications?
- Decreased hepatic enzyme activity
- Expanded plasma volume and increased body fat (Correct answer)
- Increased GI acid production
- Decreased pulmonary capacity
Correct answer: Expanded plasma volume and increased body fat
Pregnancy-related plasma volume expansion (~50%) and increased body fat increase the volume of distribution of lipophilic psychotropics, often lowering effective serum levels.
Question 3: A patient is prescribed an SNRI for perinatal depression. Which additional counseling point differentiates SNRIs from SSRIs in the perinatal context?
- SNRIs are completely contraindicated in all trimesters
- SNRIs have norepinephrine effects that may contribute to hypertension and should be monitored in preeclamptic patients (Correct answer)
- SNRIs have no neonatal adaptation syndrome risk
- SNRIs require no dose adjustments during pregnancy
Correct answer: SNRIs have norepinephrine effects that may contribute to hypertension and should be monitored in preeclamptic patients
SNRIs' noradrenergic activity can elevate blood pressure, which is especially relevant in patients at risk for or diagnosed with preeclampsia.
Question 4: A patient stabilized on aripiprazole for bipolar disorder plans to breastfeed. What is the most clinically relevant concern with this medication during lactation?
- Aripiprazole is excreted minimally and poses no risk
- Aripiprazole has been shown to suppress prolactin and may inhibit milk production (Correct answer)
- Aripiprazole causes liver toxicity in nursing infants
- Aripiprazole is the preferred atypical antipsychotic for all breastfeeding patients
Correct answer: Aripiprazole has been shown to suppress prolactin and may inhibit milk production
Aripiprazole's partial dopamine agonism can suppress prolactin, potentially reducing milk supply in breastfeeding mothers.
Question 5: What is the primary rationale for preferring lamotrigine over valproate in a woman of reproductive age with bipolar II disorder?
- Lamotrigine is more effective for mania
- Valproate carries a significantly higher teratogenic risk and is associated with fetal cognitive impairment (Correct answer)
- Lamotrigine has no drug interactions
- Valproate is not covered by most insurance plans
Correct answer: Valproate carries a significantly higher teratogenic risk and is associated with fetal cognitive impairment
Valproate's well-documented teratogenicity (neural tube defects, cognitive impairment) makes lamotrigine the preferred mood stabilizer for women who may become pregnant.
Question 6: A pregnant patient at 30 weeks develops severe insomnia. Which medication approach is most appropriate to discuss first?
- Zolpidem at standard adult doses
- Sleep hygiene and CBT-I as first-line with short-term low-dose diphenhydramine if needed (Correct answer)
- Alprazolam nightly for remainder of pregnancy
- Melatonin 20 mg nightly
Correct answer: Sleep hygiene and CBT-I as first-line with short-term low-dose diphenhydramine if needed
CBT for insomnia (CBT-I) is first-line; diphenhydramine is a relatively safer short-term option if pharmacotherapy is needed, while benzodiazepines and z-drugs carry higher fetal risk.
Question 7: Which statement about omega-3 fatty acid supplementation in perinatal mood disorders is most accurate?
- Omega-3s are FDA-approved as a standalone treatment for postpartum depression
- Evidence suggests EPA-rich omega-3s may have adjunctive benefit for perinatal depression with a favorable safety profile (Correct answer)
- Omega-3s are contraindicated in pregnancy due to mercury risk
- No evidence supports omega-3 use in perinatal psychiatric conditions
Correct answer: Evidence suggests EPA-rich omega-3s may have adjunctive benefit for perinatal depression with a favorable safety profile
EPA-dominant omega-3 formulations show adjunctive antidepressant effect in perinatal populations and are generally safe, supporting their use as a complement to evidence-based treatment.
PMH-C Psychopharmacology 5
A perinatal patient with ADHD asks about stimulant medication safety during breastfeeding.
What is the most accurate statement?